HomeInvestors & MediaNews
ABL Bio Submits an Additional Clinical Trial Amendment to Evaluate ABL103 in a Phase 1b/2 St...
- ABL103 in combination with KEYTRUDA and Taxane will be evaluated for safety and efficacy in South Korea, the United States, and Australia Pangyo (South Korea) – March 20, 2025, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has submitted an additional clinical trial amendment for the Phase 1b/2 study of ABL103 in combination with MSD’s (a subsidiary of Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) and Taxane as a triple combination therapy. ABL103 is a bispecific antibody that simultaneously targets B7-H4 and 4-1BB. ABL103 is one of the pipeline programs in which ABL Bio’s 4-1BB based bispecific antibody platform ‘Grabody-T’ has been applied. Grabody-T is designed to activate T cells only in the tumor microenvironment, potentially reducing the liver toxicity of conventional 4-1BB monoclonal antibody and enhancing the antitumor activity. A Phase 1 clinical trial evaluating ABL103 monotherapy is currently underway in the United States and South Korea. ABL Bio plans to amend the investigational new drug (IND) application for this Phase 1 trial to include a Phase 1b/2 study assessing combination therapy in South Korea, the United States, and Australia. The Phase 1b/2 study will consist of two safety lead-in parts to determine the appropriate dosage for the triple combination therapy, as well as one dose expansion part. Through this study, ABL Bio aims to evaluate the safety and efficacy of the ABL103 triple combination therapy. Sang Hoon Lee, CEO of ABL Bio said “with the submission of this clinical trial amendment, the journey to evaluate ABL103 combination therapy in solid tumor patients has officially begun. We hope that ABL103 will demonstrate strong efficacy in combination with KEYTRUDA and Taxane. Along with ABL103, clinical trials for 4-1BB-based bispecific antibodies, including ABL111/Givastomig, ABL503/Ragistomig, and ABL105, are progressing smoothly. Among them, ABL111/Givastomig is advancing the fastest in clinical development and is expected to announce the top-line results of its Phase 1b combination study this year. We appreciate your continued interest and support in our progress.” Meanwhile, ABL Bio entered a clinical trial collaboration and KEYTRUDA supply agreement with MSD in October last year to evaluate ABL103 combination therapy in patients with advanced or metastatic solid tumors. About ABL BioABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. Clinical projects for 7 pipelines, including ABL301, ABL001, ABL111/givastomig, ABL503/ragistomig, ABL105, ABL202, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. In case of ABL001, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to support the rapid development of this new drug candidate. In addition, ABL111/givastomig, co-developed with I-Mab, is expected to disclose the top-line data from the Phase 1b clinical trial in 2025, evaluating the triple combination therapy with nivolumab and chemotherapy. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs). KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
2025-03-20ablbio
ABL Bio to Host ADC Symposium
- Global ADC development experts invited as speakers to enhance ADC R&D capabilities March 10, 2025, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that it will host an ‘Antibody-Drug Conjugate (ADC) Symposium’ for biotech industry officials on March 14th. The symposium is held to enhance ADC development capabilities, which are increasingly gaining attention in the field of oncology drug development and facilitate collaboration among domestic and international ADC experts. Renowned scientists with experience developing ADCs at global pharmaceutical biotech companies will participate as session speakers. The first session, titled ‘The Past, Present, and Future of ADCs,’ will be led by Dr. Mark Sliwkowski, a former scientist at Genentech and member of the Roche Group. Dr. Sliwkowski will share insights into the history of ADCs, the success of HER2-targeted ADC Kadcyla (T-DM1), and lessons learned from past ADC development failures. The second session, titled ‘ADCs for Cancer Treatment,’ will feature Dr. Peter Senter, former scientist of Seagen and Bristol Myers Squibb, who played a key role in the development and approval of ADCs such as Padcev and Tivdak. The third session, "Insights into Clinical ADC Development," will be presented by Dr. Patrick Zweidler-McKay, a former executive at ImmunoGen, the company behind Elahere, a folate receptor alpha (FRα)-targeting ADC. Dr. Zweidler-McKay, now a consultant at his own firm, will discuss ADC clinical development for solid tumors and the therapeutic advantages of ADCs. In the fourth session, Dr. Morris Rosenberg, who previously worked at Immunomedics (developer of the TROP2-targeting ADC Trodelvy) and Seagen, will share strategies for late-stage development of ADC pipelines. The fifth and sixth sessions will cover key considerations in preclinical ADC development and clinical pharmacology of ADCs. Speakers include Dr. Laurie Tatalick, co-founder of ProfoundBio, and Dr. Tae Han, former expert of Seagen. The seventh session will feature Kai Ming-Pu, a consultant from Clearview, a global healthcare consulting firm, who will present emerging trends in ADC development. Last July, ABL Bio announced the full-scale launch of its bispecific ADC development program and secured KRW 140 billion through a third-party allotment capital increase. The company is currently recruiting executives and ADC experts for its U.S. subsidiary, ABL Bio USA, which will spearhead bispecific ADC development. ABL Bio plans to begin IND submissions for its bispecific ADC pipeline starting later this year. Sang Hoon Lee, CEO of ABL Bio said, “As the importance of ADCs in cancer drug development continues to grow, we have invited top international experts to help strengthen the capabilities of our researchers and others in the biotech industry. We’ve prepared this event to be practically helpful for ADC R&D, so we ask for a great deal of interest and participation.”
2025-03-10ablbio
ABL Bio Publishes ABL112 Study in Prestigious Journal JITC
- Activates CD8+ T cells in the tumor microenvironment like other Grabody-T-based bispecific antibodies- Lead 4-1BB bispecific antibody ABL111/Givastomig to release triple combination therapy data this year March 4, 2025, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced on the 4th that it has published a research paper on its bispecific immuno-oncology candidate ABL112 in the Journal for ImmunoTherapy of Cancer (JITC), an international journal issued by the Society for Immunotherapy of Cancer (SITC). JITC is a prestigious international journal with an Impact Factor of 10.3, featuring a wide range of studies related to tumor immunology and immunotherapy. The title of the paper published by ABL Bio is: "Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+ T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment." ABL112 is an immuno-oncology bispecific antibody developed using Grabody-T, ABL Bio’s proprietary 4-1BB-based bispecific antibody platform. Grabody-T is designed to activate CD8+ T cells selectively within the tumor microenvironment, minimizing the liver toxicity typically associated with 4-1BB monoclonal antibodies, while enhancing anti-tumor efficacy. ABL112 simultaneously targets TIGIT (T cell immunoreceptor with Ig and ITIM domains), an immune checkpoint on T cells, and 4-1BB. According to the paper, ABL112 blocks the interaction between TIGIT and CD155, which suppresses T cell activity, thereby restoring CD8+ T cell function. Unlike TIGIT-targeting monoclonal antibodies, ABL112 demonstrated long-lasting therapeutic effects. The study also confirmed strong anti-tumor activity both as a monotherapy and in combination with PD-(L)1 inhibitors. Sang Hoon Lee, CEO of ABL Bio, stated, “We are proud to publish our ABL112 research in JITC, a leading international journal that plays a key role in the field of immuno-oncology. This publication, along with other journal articles and conference presentations, helps demonstrate the excellence of ABL Bio’s 4-1BB bispecific antibody programs. This year, we look forward to sharing clinical data from our fastest advancing Grabody-T based pipeline, ABL111/Givastomig—a Claudin18.2 x 4-1BB bispecific antibody—being tested in triple combination with nivolumab and chemotherapy. We appreciate your continued interest and support.”
2025-03-05ablbio
ABL Bio Attends J.P. Morgan Healthcare Conference
- Focused discussions on BBB shuttle platform and clinical-stage immuno-oncology pipeline expected to take place January 6, 2025, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced on the 6th that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place from January 13th to 16th in San Francisco, USA, to continue discussions on various partnership opportunities. J.P. Morgan Healthcare Conference is one of the world’s largest healthcare investment events, bringing together pharmaceutical and biotech companies, medical professionals, investment banks, and venture capitalists to share the latest therapeutic technologies and explore a wide range of investment and partnership opportunities. ABL Bio has been invited to attend the conference every year since its founding, and this marks its ninth participation. During the event, ABL Bio plans to hold follow-up meetings with global pharmaceutical and biotech companies it has been in partnership talks with, while also keeping up with global trends in next-generation drug development. In particular, active discussions are anticipated around Grabody-B, the company’s Blood-Brain Barrier (BBB) shuttle platform for the treatment of neurodegenerative diseases. This focus comes in the wake of positive early results from Trontinemab, a BBB shuttle-conjugated version of Roche’s anti-amyloid beta monoclonal antibody Gantenerumab, in a Phase 1/2 clinical trial for Alzheimer’s disease- despite Gantenerumab’s prior standalone failure- making BBB shuttles a key to success in treating neurodegenerative diseases. In the field of oncology, ABL Bio will share the latest clinical data on its immuno-oncology therapeutics utilizing its Grabody-T platform, a 4-1BB-based bispecific antibody. Givastomig, currently in development for gastric cancer, is undergoing a Phase 1b trial to evaluate the safety of a triple combination therapy with chemotherapy and PD-1 inhibitor Nivolumab. Top-line data from this trial is expected in the second half of 2025. Meanwhile, Ragistomig and ABL103 are progressing smoothly in monotherapy Phase 1 clinical trials, with ABL103 set to begin early trials for combination therapy later this year. Sang Hoon Lee, CEO of ABL Bio, stated, “Since Roche’s Trontinemab opened a new era for BBB shuttles in the neurodegenerative disease treatment market, global interest in this technology has surged. As clinical data from our immuno-oncology pipeline continues to emerge, our discussions with global partners are also making remarkable progress. ABL Bio will continue to seek various growth opportunities at this conference and do our best to deliver good news soon.”
2025-01-06ablbio
ABL Bio to Participate in the 2024 Pharmaceutical Bioindustry Innovation Forum
- Accelerating development of bispecific ADCs based on bispecific antibody expertise- Aiming to submit up to three INDs for bispecific ADCs next year November 25, 2024, ABL Bio (CEO Sang Hoon Lee), ABL Bio (CEO Sanghoon Lee), a company specializing in bispecific antibodies, announced that it will attend the "2024 Pharmaceutical & Bioindustry Innovation Forum: Antibody-Drug Conjugate (ADC) Development Trends and Strategies", hosted by the Korea Health Industry Development Institute (KHIDI) on November 27th. At the forum, the company will present its strategies and progress in developing bispecific ADCs. ADCs are a cutting-edge modality in oncology that combine an antibody targeting specific tumor antigens with a highly potent cytotoxic payload to selectively kill cancer cells. Since AstraZeneca and Daiichi Sankyo achieved global success with their HER2-targeting ADC (Enhertu), ADCs have become a focal point of drug development efforts among pharmaceutical and biotech companies worldwide, including Korea. Building on its bispecific antibody expertise and experience co-developing the ROR1-targeting ADC ABL202 (CS5001/LCB71) with LigaChem Biosciences, ABL Bio is currently developing bispecific ADCs. Compared to traditional monoclonal ADCs, bispecific ADCs offer enhanced efficacy and safety by improving the precision of payload delivery to tumor cells. Global interest in bispecific ADCs is growing rapidly—Bristol Myers Squibb recently acquired a U.S.-based Phase 1-stage bispecific ADC asset with an upfront payment of $800 million (approximately 1 billion KW), and companies like Sotio and IDEAYA Biosciences have secured bispecific ADC technologies through licensing deals. At the forum, Vice President Weon Kyoo You of ABL Bio will present on the strengths, potential, and pipeline of the company’s bispecific ADCs currently in the preclinical stage. Sang Hoon Lee, CEO of ABL Bio, stated, “ADCs have now become one of the most important modalities in oncology. We are pleased to join this event to share the latest insights and developments with leading domestic and global ADC innovators. ABL Bio is intensifying its R&D efforts with the goal of submitting up to three Investigational New Drug (IND) applications for bispecific ADCs in 2025. Since the bispecific ADC field is still in its early stages, we are committed to becoming a market leader through rapid development and early entry.”
2024-11-25ablbio
ABL Bio/I-Mab Present ABL111/Givastomig Data at SITC 2024
- ABL111/givastomig is a bispecific antibody targeting Claudin 18.2 (CLDN 18.2)-positive tumor cells that conditionally activates T cells via 4-1BB in the tumor microenvironment, with potential CLDN 18.2 specificity even in tumors with low levels of CLDN 18.2 expression- Poster highlights Phase 1 pharmacokinetic modeling data for dose optimization of givastomig- The optimal dose of ABL111/givastomig is identified as 8-12 mg/kg dosed every two weeks (Q2W) ABL Bio (CEO Sang Hoon Lee, “ABL”), a company specializing in bispecific antibodies, today announced that its partner I-Mab presented the Phase I pharmacokinetic modeling clinical of ABL111/givastomig (TJ033721), at the 39th Annual Meeting for the Society for Immunotherapy of Cancer (SITC 2024) 2024, held in Houston, Texas from November 8th through 10th. Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB. It is being evaluated in ongoing Phase 1b dose expansion and combination studies in treatment-naive metastatic gastric cancers. The poster highlighted the dose optimization analysis for givastomig monotherapy using data from three clinical studies and non-clinical experiments. The poster entitled “Optimal dose estimation using an integrated approach from Phase I data of givastomig, a novel Claudin18.2×4-1BB bispecific antibody” was presented on November 9, 2024, in the Poster Hall of the George R. Brown Convention Center. The studies demonstrated a dose-response relationship for givastomig and identified 8-12 mg/kg Q2W as the optimal monotherapy dose range for gastric cancer patients. ABL Bio and I-Mab are currently conducting a Phase 1b study evaluating givastomig in combination with nivolumab plus chemotherapy in patients with treatment-naïve Claudin18.2-positive metastatic gastric cancers. “ABL111/givastomig is an investigational agent that was developed based on the company’s Grabody-T platform. Our Grabody-T platform has led to promising product candidates, enhanced by our efforts to advance and optimize the 4-1BB technology in our bispecific antibodies,” said Sang Hoon Lee, CEO of ABL Bio. “Givastomig appears to maintain strong tumor binding and anti-tumor activity, while minimizing liver toxicity and systemic immunotoxicity commonly seen with other emerging 4-1BB-based product candidates. Top line data are expected in H2 2025 from the Phase 1b dose escalation clinical trial evaluating the combination of givastomig plus nivolumab and chemotherapy.” About ABL111/givastomig Givastomig (TJ033721/ABL111) is a bispecific antibody targeting Claudin (CLDN) 18.2-positive tumor cells. It conditionally activates T cells in the tumor microenvironment where CLDN18.2 is expressed using 4-1BB. Activated T cells attack Claudin 18.2-positive tumor cells while preserving normal cells, potentially avoiding potential for serious liver toxicity. . In March 2022, ABL111/givastomig received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) as a treatment for gastric cancer (including gastroesophageal junction cancer). Givastomig, is being jointly developed through a global partnership with I-Mab. ABL shares worldwide rights with I-Mab equally, excluding China and South Korea, where ABL retains full rights. About ABL Bio ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. More than 15 clinical projects for over 7 programs, including ABL001, ABL111/givastomig, ABL503/ragistomig, ABL105, ABL202, ABL301, and ABL103, are directed at important cancer targets such as PD-L1, Claudin 18.2, B7-H4 and HER-2, and are underway for different indications in various countries, including the United States, China, Australia, and Korea. ABL’s lead program, ABL001, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to support the rapid development of this new drug candidate. The program recently completed patient enrollment in a Phase 2/3 clinical trial for biliary tract cancer, and the top-line data will be disclosed in 2025. In addition, encouraging Phase 1 data were just presented at the European Society of Medical Oncology (ESMO2024) for ABL111/givastomig, in development with I-Mab for gastric cancers (including gastroesophageal junction, GEJ). Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs). Note: this is a translated version of the original Korean language document, prepared and provided solely for readers’ convenience. In case of any discrepancy or dispute, the Korean language document prevails.
2024-11-13ablbio
ABL Bio Presents 4-1BB Bispecific Antibody Platform Grabody-T at PEGS Europe
- Grabody-T overcomes liver toxicity of 4-1BB monoclonal antibodies through bispecific structure- Clinical development of 4-1BB bispecific antibodies is progressing well… Company exploring various business opportunities November 8, 2025, ABL Bio (CEO Sang Hoon Lee), ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that it participated in the 16th Annual Protein & Antibody Engineering Summit (PEGS Europe), held in Barcelona, Spain, from November 5th to November 7th. PEGS Europe is the largest European event where industry experts and global pharmaceutical and biotech companies gather to share expertise and the latest insights on protein and antibody engineering. ABL Bio CEO Sang Hoon Lee personally attended the event and delivered an oral presentation in the session titled "Antibody-based Cancer Therapies: Overcome Efficacy and Toxicity Challenges," introducing the company’s 4-1BB-based bispecific antibody platform, Grabody-T. The title of the presentation was: "4-1BB T cell Engaging BsAb (Grabody-T) Activated T Cells only in the Tumor Microenvironment and Demonstrated Superior Efficacy and Safety Profile." 4-1BB is a protein involved in the activation of T cells, a type of immune cell. 4-1BB monoclonal antibodies work by stimulating T cells to attack cancer cells. The first developer of a 4-1BB monoclonal antibody was Bristol Myers Squibb, whose candidate demonstrated strong anticancer efficacy. However, due to severe liver toxicity caused by 4-1BB activation in the liver, clinical development was halted. Grabody-T was developed in a bispecific antibody format to overcome these limitations of 4-1BB monoclonal antibodies. Bispecific antibodies can be designed to target tumor antigens such as Claudin18.2 or HER2, ensuring that T cell activation occurs only within the tumor microenvironment. Clinical-stage bispecific immuno-oncology drug candidates based on Grabody-T include Ragistomig, Givastomig, ABL103, and ABL105. Notably, interim Phase 1 clinical results for Givastomig, presented at the European Society for Medical Oncology (ESMO), showed no serious liver toxicity. Currently, Givastomig is in a Phase 1b clinical trial in the U.S., in combination with chemotherapy and nivolumab. Ragistomig is undergoing a Phase 1 monotherapy trial in the U.S. and Korea. ABL103 is in a domestic Phase 1 monotherapy trial, while ABL105 is in a Phase 1/2 trial led by license partner Yuhan Corporation in Australia and Korea. CEO Sang Hoon Lee stated, “We are pleased to introduce our 4-1BB based bispecific antibody platform to antibody experts around the world. ABL Bio is overcoming the intrinsic liver toxicity challenges of 4-1BB- where even global pharmaceutical companies have failed- by developing it in a bispecific format. Although the Grabody-T-based candidates are still in Phase 1, they are already showing promising clinical data, which has led to clinical collaboration and supply agreements with global pharma. This demonstrates the broader potential value of other 4-1BB bispecific antibodies. We will continue to promote the value of the Grabody-T platform and seek out various business opportunities moving forward.”
2024-11-08ablbio
ABL Bio will Present Bispecific ADC development strategy at World ADC San Diego
- The company aims to be the leader of the bispecific ADC market ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it will attend 'World ADC San Diego' held in USA from November 4th to 7th to introduce its bispecific Antibody Drug Conjugate (ADC) development strategy. World ADC is the largest ADC specialized event celebrating its 15th anniversary this year, where various participants interested in ADC gather to discuss ADC development strategies and new technologies. ABL Bio was invited to attend this event as a program speaker, and the presentation title is ‘Bispecific ADC as Next Generation of ADC may Overcome Current Clinical Limitations.’ The presentation will include non-clinical data on the bispecific ADC pipeline that ABL Bio is developing. ABL Bio is developing bispecific ADC as a new driving force for growth into a global bio company. The success of ADC is depending on safe delivering of a larger amount of payload to tumor cells. In the case of bispecific ADC, compared to monoclonal ADC, the payload is delivered to tumor cells more accurately, thereby improving safety and anticancer efficacy, and it is possible to block the tumor cell's evasion mechanism. Tumor cells acquire resistance to anticancer drugs by activating other circuits that can compensate for the blockage of the existing signal transmission systems. However, bispecific ADC can suppress tumor cell's acquisition of resistance by simultaneously targeting two antigens that have a compensatory relationship with each other. Sang Hoon Lee, CEO of ABL Bio said "as the development of bispecific ADC has become an important topic, we are receiving requests to share ABL Bio's bispecific ADC development strategy at various events. Bispecific ADC market is still in its early stages. We expect to take the leadership in this market through rapid entry. We will do our best to submit INDs for bispecific ADC pipelines by next year by focusing on ongoing non-clinical development of them." Meanwhile, ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. More than 15 clinical projects for over 7 pipelines, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. ABL’s lead program, ABL001, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to support the rapid development of this new drug candidate. The program recently completed patient enrollment in a Phase 2/3 clinical trial for biliary tract cancer and the top-line data will be disclosed in 2025. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs). Note: this is a translated version of the original Korean language document, prepared and provided solely for readers’ convenience. In case of any discrepancy or dispute, the Korean document prevails.
2024-11-01ablbio
ABL Bio Participates in BIO Europe 2024
- Exploring various business opportunities based on its 4-1BB based bispecific antibodies and BBB shuttle platforms ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it will attend BIO Europe 2024 to explore various business opportunities. Bio Europe is the largest bio conference in Europe, with over 2,800 pharmaceutical and bio companies and over 5,500 industry professionals. Bio Europe is held twice a year, in spring and fall, and the fall event that ABL Bio is participating in will be held in Stockholm, Sweden from November 4th to 6th. At this event, ABL Bio plans to meet with various global pharmaceutical and bio companies to share the latest clinical data of its immuno-oncology pipelines utilizing the 4-1BB-based bispecific antibody platform ‘Grabody-T’. The clinical-stage 4-1BB-based bispecific antibodies of ABL Bio are ABL503/ragistomig, ABL111/givastomig, and ABL103, all of which are in the Phase 1 clinical stage. ABL503/ragistomig presented the interim results of a Phase 1 clinical trial for monotherapy at the American Society of Clinical Oncology (ASCO) this year, and ABL111/givastomig additionally disclosed the results of a Phase 1 clinical trial for monotherapy at the recent European Society for Medical Oncology (ESMO). ABL103 is currently undergoing a Phase 1 dose escalation part in Korea. ABL Bio will also have a meeting to discuss on its Blood Brain Barrier (BBB) shuttle platform, 'Grabody-B'. As interest in BBB shuttle is increasing globally, ABL Bio expects that there will be many meaningful meetings at this event. Sang Hoon Lee, CEO of ABL Bio said "starting with the J.P. Morgan Healthcare Conference early this year, we have been continuing meeting with global pharmaceutical and bio companies at events including BIO USA and BIO Europe to share the latest clinical data. In addition to the development of existing pipelines, ABL Bio is also focusing on the development of bispecific ADCs (Antibody Drug Conjugate). We plan to do our best to communicate with various industry players around the world to understand the trends and not miss any business opportunities." Meanwhile, ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. More than 15 clinical projects for over 7 pipelines, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. ABL’s lead program, ABL001, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to support the rapid development of this new drug candidate. The program recently completed patient enrollment in a Phase 2/3 clinical trial for biliary tract cancer and the top-line data will be disclosed in 2025. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs). Note: this is a translated version of the original Korean language document, prepared and provided solely for readers’ convenience. In case of any discrepancy or dispute, the Korean document prevails.
2024-10-30ablbio